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The trends in coronary heart disease (CHD) mortality rates differ widely across countries.1 In Europe, there is a north-
east to southwest gradient in age-standardized CHD mortal-
ity,2 and Portugal has been a low-risk country for decades.3 
Although the CHD mortality rates have been declining since 
the 1980s, more steeply after the mid-1990s, particularly 
among women,1,3 CHD remains the second most common 
cause of death in Portugal.4
A high prevalence of hypertension and high stroke mortality 
are distinguishing features of the cardiovascular disease epi-
demiology in Portugal.5 However, the risk factor distributions 
changed in the past several decades, with steep decreases in 
blood pressure levels since the 1970s,6 a decrease in the preva-
lence of smoking among men but increase among women,7 
and an increase in the frequency of obesity in the younger 
age groups.8 In addition, there were several improvements in 
the management of CHD, namely, in the availability of drug 
treatments, in the access to reperfusion and revascularization 
interventions, with the development of a hospital referral net-
work for interventional cardiology, and the implementation of 
a coronary fast track system.9
It is important to assess the relative contribution of these 
underlying factors to the observed decline in CHD mortality 
in different settings, plan future health policy, and prioritize 
strategies for primary and secondary prevention. The IMPACT 
model, a cell-based policy model, uses epidemiological infor-
mation to estimate the contributions of population-level risk 
factor changes (impacting mainly on incidence) and changes 
in the uptake of evidence-based treatments (impacting mainly 
on case fatality) on mortality decline between 2 points in time 
(the start year and the end year). In the present investigation, 
we aimed to model the decline in CHD mortality between 
1995 and 2008 in Portugal, quantifying the contribution of 
changes in the use of evidence-based treatments and in the 
levels of major cardiovascular risk factors using IMPACT.
Methods
IMPACT CHD Mortality Model
We used an updated version of the IMPACT CHD mortality model to 
investigate how changes in risk factors and treatments have affected 
the substantially decreasing mortality rates in CHD among men and 
women 25 to 84 years of age in Portugal. The IMPACT model has 
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been used previously in diverse populations, namely, in the United 
States,10 New Zealand,11 China,12 and Europe,13 including other 
Southern European populations, namely, Italy14 and Spain.15
The IMPACT model incorporates data on trends in the distribu-
tion of the main cardiovascular risk factors: high systolic blood pres-
sure (SBP), smoking, high total cholesterol, high body mass index 
(BMI), diabetes mellitus, and physical inactivity. It also includes ≈50 
evidence-based treatments for all CHD patient groups: acute myo-
cardial infarction (AMI), cardiac arrest, unstable and chronic angina, 
and mild and acute heart failure (Appendix in the online-only Data 
Supplement). The model compares data from a baseline year (1995) 
against data observed in a more recent year (2008). The main out-
come of the model is the relative contributions of cardiovascular risk 
factors and treatment groups to CHD mortality decline, measured as 
deaths prevented or postponed (DPPs). The calculation of the relative 
contributions is based on the well-studied relationships between each 
risk factor change and the relative reduction in CHD mortality and 
between treatment uptake and reductions in case-fatality in patients 
with a specific form of CHD.
Number of DPPs
The starting point for the model is to calculate the target number of 
deaths the model needs to explain. Data on the total population and the 
number of CHD deaths for Portugal, according to the International 
Classification of Diseases (ICD), in 1995 and 2008, were obtained 
from the Portuguese official statistics, by 10-year age bands.4
We calculated the number of CHD deaths expected in 2008 if 
the CHD mortality rates in 1995 had persisted by multiplying the 
age-specific mortality rates for 1995 by the population for each 10-
year age stratum in the year 2008 (ie, simple direct standardization). 
Subtracting the number of observed deaths in 2008 from the number 
of expected deaths generates the reduction in the number of CHD 
deaths in 2008, which the model aims to explain. We will refer to 
them as DPPs.
Identification and Assessment of Relevant Data
To build the Portuguese IMPACT model, we used specific data 
from the Portuguese population whenever possible. When >1 
data source was available, we chose the most representative and 
least biased source. A detailed description of all the sources 
of data used is found in the Appendix in the online-only Data 
Supplement.
Data on number of patients admitted to a hospital with myocardial 
infarction, unstable angina, and heart failure were obtained from the 
National Hospital Discharge Registry, centrally held in the Central 
Administration of the Health System for Portugal.16 The proportion 
of patients treated for myocardial infarction, unstable angina, or 
heart failure during hospitalization were obtained from clinical epi-
demiological studies on samples of patients consecutively admitted 
to Portuguese hospitals.17,18 The number of patients in the community 
eligible for treatments for chronic angina and heart failure and for 
statin therapy to reduce cholesterol and antihypertensive medications 
to control blood pressure was obtained from epidemiological studies 
on representative samples of the general Portuguese population; the 
proportion of patients treated for those conditions were taken from 
the same studies.19,20
Data on the effectiveness of therapeutic interventions, on the 
 association between cardiovascular risk factors and CHD mortality 
and case-fatality rates, were obtained from published meta-analyses, 
randomized controlled trials, and international cohort studies (see 
Appendix in the online-only Data Supplement).
In 1995, data on mean total cholesterol, mean SBP, mean BMI, 
and prevalence of diabetes mellitus were obtained from a systematic 
review that summarizes the evidence from studies providing data on 
the distribution of risk factors in Portuguese adults.6,21,22 Data on the 
prevalence of smoking and physical inactivity were obtained from 
the National Health Survey conducted from 1995 to 1996.23 Data of 
risk factors in 2008 were obtained from 2 cross-sectional studies in 
random samples of the general population.20,24
Mortality Reductions Attributable to Treatments
The analysis of the contribution of treatments is reported for men and 
women together after confirming that in this population, no important 
sex heterogeneity was found in these results. Therefore, the propor-
tional contribution of each treatment presented in the Results section 
and Figure 2 was computed using all DPPs as the denominator.
The DPPs associated with a specific CHD treatment within a dis-
ease subgroup at a specific time point (in either 2008 or 1995 for 
treatments available at that time) was estimated by taking the product 
of the number of people in the subgroup by the proportion of those 
patients who received the particular treatment at that time, 1-year 
case-fatality rates, and the relative risk reduction attributed to that 
specific treatment based on the published literature (Table 1).
We assumed that the compliance (proportion of treated patients 
actually taking therapeutically effective levels of medication) was 
100% among hospital patients, 70% among symptomatic commu-
nity patients, and 50% among asymptomatic community patients
.
25,26 
To avoid double counting of patients treated, we identified potential 
overlaps between different groups of patients and made appropriate 
adjustments (Appendix in the online-only Data Supplement). To ad-
dress the potential effect of multiple treatments in the same patient 
on the relative reduction in case-fatality rate, we used the Mant and 
Hicks cumulative relative benefit approach27 (Appendix in the online-
only Data Supplement).
.
The effect of the increase in the use of treatments from 1995 to 
2008 was assessed by subtracting the DPPs attributable to each treat-
ment in 1995 from those in 2008.
Mortality Reductions Attributable to Changes in 
Risk Factors
The time trends in risk factors followed different patterns in men and 
women, resulting in heterogeneous contribution to the CHD mortality 
decline. The results of the analysis of the contribution of risk fac-
tors are therefore presented by sex, and the proportional contribution 
WHAT IS KNOWN
•	 Trends in coronary heart disease mortality rates dif-
fer widely across countries; Portugal has been a low-
risk country for decades.
•	 Coronary heart disease mortality rates in Portugal 
have been declining since the 1980s, more steeply 
after the mid-1990s, particularly among women.
•	 A relatively high prevalence of hypertension and 
high stroke mortality are distinguishing features of 
the cardiovascular disease epidemiology in Portugal.
WHAT THE STUDY ADDS
•	 Approximately half of the coronary heart disease 
deaths prevented or postponed between 1995 and 
2008 were attributed to increasing use of evidence-
based therapies.
•	 Approximately 42% of the decline was attributable 
to the trends in major risk factors, mainly systolic 
blood pressure, although the rise in the prevalence 
of diabetes mellitus and mean body mass index in 
both sexes and in smoking prevalence among women 
generated additional deaths.
•	 The proportional contribution of treatments and risk 
factors for coronary heart disease mortality trends in 
Portugal differs from other countries mainly because 
of a higher contribution of treatments.
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Table 1. Estimated CHD Deaths Prevented or Postponed by Treatments in Portugal, 1995 to 2008
No. of Eligible Patients*
Treatment 
Uptake†
Relative Risk 
Reduction
Case-Fatality 
Rate
No. of Deaths Prevented or Postponed‡
Best Estimate* (Minimum Estimate; Maximum Estimate)
1995 2008 1995 2008 1995 2008
Increase in 
DPPs (DPPs in 
2008 minus 
DPPs in 1995)
Acute phase disease management
  AMI
   Community CPR 0 1770 0.00 0.01 0.05 0.110 0 (0; 0) 0 (0; 0) 0 (0; 0)
   Hospital CPR 255 510 0.03 0.05 0.31 0.101 0 (0; 5) 5 (5; 15) 5 (5; 10)
   Thrombolysis 7050 11 800 0.04 0.07 0.23 0.101 5 (0; 10) 10 (5; 25) 5 (5; 15)
   Aspirin 7050 11 800 0.70 0.78 0.15 0.110 70 (30; 145) 115 (45; 230) 45 (15; 85)
   β-Blocker 7050 11 800 0.35 0.63 0.04 0.110 10 (5; 20) 25 (10; 50) 15 (5; 30)
   ACE-inhibitor 7050 11 800 0.32 0.59 0.07 0.110 15 (5; 30) 40 (15; 85) 25 (10; 55)
   PCI (STEMI) 7050 11 800 0.00 0.60 0.32 0.110 0 (0; 0) 170 (70; 355) 170 (70; 355)
   PCI (NSTEMI) 7050 11 800 0.00 0.35 0.32 0.110 0 (0; 0) 95 (40; 190) 95 (40; 190)
   CABG 7050 11 800 0.00 0.02 0.20 0.110 0 (0; 0) 5 (0; 10) 5 (0; 10)
   Cardiac 
rehabilitation
7050 11 800 0.00 0.02 0.26 0.110 0 (0; 0) 0 (0; 5) 0 (0; 5)
  Total AMI … … … … … … 100 (40; 205) 470 (195; 960) 370 (155; 760)
  Unstable angina
   Aspirin and heparin 3310 2275 0.00 0.56 0.33 0.069 0 (0; 0) 20 (10; 45) 20 (10; 45)
   Aspirin 3310 2275 0.70 0.79 0.15 0.069 20 (10; 45) 15 (5; 25) −5 (−5; −20)
   Platelet glycoprotein 
IIB/IIIA inhibitors
3310 2275 0.00 0.17 0.09 0.069 0 (0; 0) 0 (0; 5) 0 (0; 5)
   CABG 3310 2275 0.00 0.01 0.43 0.069 0 (0; 0) 0 (0; 0) 0 (0; 0)
   PCI 3310 2275 0.00 0.33 0.32 0.069 0 (0; 0) 10 (5; 23) 10 (5; 23)
  Total unstable angina … … … … … … 20 (10; 45) 50 (20; 100) 30 (10; 55)
  Total AMI+unstable 
angina
… … … … … … 120 (50; 245) 530 (215; 1060) 410 (165; 815)
Secondary prevention
  Post-AMI
   Aspirin 27 555 52 840 0.179 0.355 0.150 0.070 20 (5; 55) 75 (25; 190) 55 (20; 135)
   β-Blocker 27 555 52 840 0.157 0.310 0.230 0.070 30 (10; 70) 100 (35; 250) 70 (25; 180)
   ACE-inhibitor 27 555 52 840 0.142 0.281 0.200 0.070 25 (5; 55) 80 (25; 205) 55 (20; 150)
   Statin 27 555 52 840 0.181 0.360 0.220 0.070 30 (10; 65) 105 (35; 255) 75 (25; 190)
   Warfarin 27 555 52 840 0.008 0.015 0.220 0.070 0 (0; 5) 5 (0; 15) 5 (0; 10)
   Cardiac 
rehabilitation
27 555 52 840 0.008 0.015 0.260 0.070 0 (0; 5) 5 (0; 15) 5 (0; 15)
  Total secondary prevention post-AMI … … … … … 105 (25; 185) 375 (125; 930) 265 (100; 750)
  Post-CABG/PCI
   Aspirin 0 26 440 0.422 0.849 0.150 0.018 0 (0; 0) 15 (10; 80) 15 (10; 80)
   β-Blocker 0 26 440 0.360 0.710 0.230 0.018 0 (0; 0) 15 (15; 100) 15 (15; 100)
   ACE-inhibitor 0 26 440 0.329 0.661 0.200 0.018 0 (0; 0) 15 (10; 85) 15 (10; 85)
   Statin 0 26 440 0.000 0.781 0.220 0.018 0 (0; 0) 15 (15; 110) 15 (15; 110)
   Warfarin 0 26 440 0.009 0.029 0.220 0.018 0 (0; 0) 0 (0; 5) 0 (0; 5)
   Cardiac 
rehabilitation
0 26 440 0.025 0.041 0.260 0.018 0 (0; 0) 0 (0; 5) 0 (0; 5)
  Total post-CABG/PCI … … … … … … 0 (0; 0) 60 (50; 385) 60 (50; 385)
  Chronic angina
   Aspirin 57 590 115 180 0.35 0.41 0.15 0.07 105 (34; 260) 120 (80; 255)
(Continued )
D
ow
nloaded from
 http://ahajournals.org by on July 26, 2018
Pereira et al  Explaining the Decline in CHD Mortality, Portugal  637
presented in the Results section and Figure 2 was computed using the 
DPPs in each sex as the denominator.
Two approaches were used to calculate the DPPs as a result of 
changes in risk factors. We used a regression approach for continu-
ous variables, namely, for SBP, cholesterol, and BMI. The number of 
DPPs as a result of the change in the mean of value for each risk fac-
tor (Table 2) was estimated as the product of 3 variables: the number 
of CHD deaths observed in 1995 (the baseline year), the absolute 
reduction in that risk factor, and the regression coefficient quantifying 
the independent association between population change in a specif-
ic cardiovascular risk factor and the consequent change in mortal-
ity from CHD. For dichotomous variables, a population-attributable 
risk fraction approach was used to determine the impact of changing 
prevalence of smoking, diabetes mellitus, and physical inactivity. The 
population-attributable risk fraction was calculated conventionally 
as (P×(RR−1))/(1+P×(RR−1)), where P is the prevalence of the risk 
factor and RR is the relative risk for CHD mortality associated with 
that risk factor (Appendix in the online-only Data Supplement). The 
number of DPPs was then estimated as the number of deaths from 
CHD expected in 2008 if 1995 rates had persisted multiplied by the 
difference between the population-attributable risk fraction in 2008 
and that in 1995 (Table 2).
To separate the DPPs explained by SBP and total cholesterol into 
those resulting from pharmacological treatment of hypertension and 
hyperlipidemia versus lifestyles changes, we subtracted the age- and 
sex-specific DPPs calculated in the treatment section (ie, statins for 
primary prevention and hypertension treatments) from the DPPs cal-
culated in the risk factor section for the variation in mean total cho-
lesterol and SBP.
Because independent regression coefficients and relative risks for 
each risk factor were taken from multivariable analyses, we assumed 
that there was no further confounding between the treatment and risk 
factor sections of the model or among the major risk factors.
The numbers of DPPs as a result of risk factor changes were quan-
tified systematically for each specific age and sex group to account 
for potential differences in effect. Lag times between the change in 
the risk factor rate and event rate change were not modeled; we as-
sumed that lag times were relatively unimportant during a period of 
13 years; also, lag times are not expected to have changed signifi-
cantly during the period of analysis.28
   Statin 57 590 115 180 0.00 0.48 0.22 0.07 0 (0; 0) 155 (80; 390) 155 (80; 390)
  Total chronic angina … … … … … … 105 (70; 260) 280 (185; 640) 175 (120; 380)
  Heart failure with hospital admission
   ACE-inhibitor 575 675 0.26 0.530 0.200 0.225 0 (0; 5) 5 (0; 15) 5 (0; 10)
   β-Blocker 575 675 0.00 0.602 0.350 0.225 0 (0; 0) 10 (0; 30) 10 (0; 30)
   Spironolactone 575 675 0.00 0.231 0.300 0.225 0 (0; 0) 5 (0; 10) 5 (0; 10)
   Aspirin 575 675 0.23 0.459 0.150 0.225 0 (0; 5) 5 (0; 10) 5 (0; 5)
  Total heart failure with 
hospital admission
… … … … … … 5 (0; 10) 20 (5; 60) 15 (5; 50)
  Heart failure in the community
   ACE-inhibitor 30 575 40 765 0.10 0.479 0.200 0.081 15 (5; 50) 90 (25; 275) 75 (20; 225)
   β-Blocker 30 575 40 765 0.00 0.320 0.350 0.081 0 (0; 0) 145 (45; 360) 145 (45; 360)
   Spironolactone 30 575 40 765 0.00 0.040 0.310 0.081 0 (0; 0) 15 (5; 40) 15 (5; 40)
   Aspirin 30 575 40 765 0.00 0.300 0.150 0.081 0 (0; 0) 60 (20; 145) 60 (20; 145)
  Total heart failure in 
the community
… … … … … … 15 (5; 45) 310 (95; 815) 295 (90; 775)
Primary prevention
  Statins for primary 
prevention
1 037 176 2 074 350 0.00 0.273 0.215 0.007 0 (0; 0) 215 (55; 645) 215 (55; 645)
  Hypertension 
treatments
2 883 717 3 310 225 0.36 0.628 0.130 0.008 210 (55; 625) 675 (135; 1680) 465 (80; 1050)
Total primary prevention … … … … … … 210 (55; 625) 890 (170;  
3825)
680 (115;  
1735)
Total treatments … … … … … … 560 (125; 820) 2450 (865; 
6220)
1890 (660; 
4845)
ACE indicates angiotensin-converting enzyme; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; CHD, coronary heart disease; CPR, cardiopulmonary 
resuscitations; DPPs, deaths prevented or postponed; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, 
ST-segment–elevation myocardial infarction.
*Numbers were rounded to nearest 5; totals may therefore not always be exact.
†Proportion of patients who received prescription for the treatment. These values were subsequently adjusted assuming that compliance was 100% among hospital 
patients, 70% among symptomatic community patients, and 50% in asymptomatic individuals taking statins or antihypertensives for primary prevention.
‡The numbers reported were obtained after adjustment for polypharmacy.
Table 1. Continued
No. of Eligible Patients*
Treatment 
Uptake†
Relative Risk 
Reduction
Case-Fatality 
Rate
No. of Deaths Prevented or Postponed‡
Best Estimate* (Minimum Estimate; Maximum Estimate)
1995 2008 1995 2008 1995 2008
Increase in 
DPPs (DPPs in 
2008 minus 
DPPs in 1995)
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Comparison of Estimated With Observed  
Mortality Changes
The estimates from the model for the total number of DPPs explained 
by each treatment and each risk factor change were rounded to the 
nearest multiple of 5 deaths. Any shortfall in the overall model esti-
mate was then presumed to be attributable to either inaccuracies in 
our model estimates or other unmeasured risk factors. Estimates were 
then summed and compared with the observed changes in mortality 
for men and women in each age group (Figure 1).
Sensitivity Analyses
Given the uncertainty surrounding many of the values input in the 
model, multiway sensitivity analyses were performed using the 
analysis of extremes method.29 For each variable in the model, we 
Table 2. Estimated CHD Deaths Prevented or Postponed as a Result of Population Risk Factor Changes in Portugal, 1995 to 2008
Absolute Level of 
Risk Factor Change in Risk Factor
Regression 
Coefficient* Relative Risk†
Deaths Prevented or 
Postponed
Best Estimate‡
(Minimum Estimate; 
Maximum Estimate)1995 2008 Absolute Relative
Mean systolic blood pressure, mm Hg§
  Men 137.5 131.0 6.5 0.047 −0.033 … 845 (560; 1165)
  Women 139.0 126.3 12.4 0.093 −0.040 … 1165 (795; 1555)
Smoking prevalence, %
  Men 32.3 25.6 6.6 0.214 … 3.03 235 (150; 335)
  Women 6.9 10.3 −3.4 −0.812 … 3.92 −35 (−25; −50)
Mean total cholesterol, mmol/L§
  Men 5.40 5.30 0.10 0.008 −0.604 … 390 (225; 490)
  Women 5.26 5.22 0.05 0.002 −0.588 … 200 (115; 250)
Mean body mass index, kg/m2
  Men 26.16 27.80 −1.64 −0.063 0.028 … −135 (−80; −210)
  Women 26.62 28.23 −1.61 −0.060 0.027 … −85 (−45; −130)
Diabetes mellitus prevalence, %
  Men 5.3 10.2 −4.9 −0,654 … 2.39 −395 (−255; −570)
  Women 6.2 6.3 −0.1 −0.022 … 3.30 −30 (−20; −40)
Physical inactivity prevalence, %
  Men 90.1 67.0 23.2 0.260 … 1.32 75 (45; 105)
  Women 92.9 72.4 20.5 0.532 … 2.28 30 (20;40)
Total risk factors … … … … … … 2260 (1490; 2945)
Total risk factors minus statins and 
antihypertensive medication
… … … … … … 1575 (1355; 1880)
CHD indicates coronary heart disease.
*Units are (log transformed) percent change in mortality rate per unit of risk factor.
†Relative risk estimates of CHD mortality for the presence versus absence of each risk factor.
‡Numbers of deaths prevented or postponed were rounded to nearest 5; totals may therefore not always be exact.
§Deaths prevented or postponed because of the reduction in the mean values of the risk factor, independently of the reasons for this decline (pharmacological 
treatment or lifestyles changes).
Figure 1. Comparison between model estimates and observed reductions in deaths from coronary heart disease in Portugal, 1995 to 2008.
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assigned a lower value and an upper value, using 95% confidence in-
tervals when available and otherwise using ±20% (for the number of 
patients, use of treatment, and compliance). For treatments assumed 
as 0, no uncertainty analysis was performed.
Detailed information on all methods is shown in the Appendix in 
the online-only Data Supplement.
Results
From 1995 to 2008, the age-adjusted mortality rate of CHD 
fell from 157.7 to 112.3 cases per 100 000 population among 
men aged 25 to 84 years and from 113.3 to 89.1 among women 
of the same age range. This resulted in 3760 fewer deaths in 
2008, 2136 in men and 1624 in women, compared with the 
expected number if the rates in 1995 had persisted.
Approximately 3465 (92%) of the estimated decrease in 
number of deaths between 1995 and 2008 could be explained 
using the Portugal IMPACT model. The remaining 8% were 
attributed to changes in other unmeasured factors. Under the 
assumptions of the sensitivity analysis, the extreme minimum 
and the maximum number of deaths from CHD that were 
explained were 2015 (54%) and 6725 (180%). The agree-
ment between the estimated and observed mortality decreases 
for men and women in each age group was generally good, 
except for men aged 65 to 74 years of age, where the model 
explained less than the observed DPPs, and women aged 
75 to 84 years, where the model predicted more DPPs than 
observed (Figure 1).
Treatments
Treatments together prevented or postponed ≈1890 deaths 
(minimum estimate, 660; maximum estimate, 4845) related 
to CHD (Table 1). These treatment effects together explained 
≈50% of the mortality reduction. The largest reductions came 
from the use of antihypertensive medication (12%) and initial 
treatments for AMI or unstable angina (11%). Within initial 
AMI treatments, the largest contributions came from percuta-
neous coronary intervention and aspirin.
The mortality decreases attributable to secondary preven-
tion after AMI and heart failure treatments were 7% and 8%, 
respectively. Smaller proportions were explained by primary 
prevention using statins (6%) and treatment of chronic angina 
(5%). Secondary prevention after coronary artery bypass sur-
gery and percutaneous coronary intervention accounted for 
<2% of deaths DPPs (Table 1).
Risk Factors
Changes in the major cardiovascular risk factors together 
accounted for ≈1575 fewer deaths (42%; minimum estimate: 
1225; maximum: 2310; Table 2), 630 (29%) among men 
and 945 (58%) among women, after subtracting the effect of 
statins and antihypertensive treatment for primary prevention.
Decreases in mean population SBP, by 6.5 mm Hg in men 
and 12.4 mm Hg in women, were estimated to have contrib-
uted to 40% of the decrease in deaths in men and 72% in 
women. This difference was mainly attributable to lifestyle 
changes because the effect of antihypertensive treatment was 
smaller in men and women (13% and 12%, respectively). 
Mean population total cholesterol levels decreased by 0.10 
mmol/L in men and 0.05 mmol/L in women, contributing to 
18% of the estimated decrease in DPPs in men and 12% in 
women, approximately half attributable to lifestyle changes 
and half to the use of statins. Physical inactivity prevalence 
decreased by 23.2% in men and 20.5% in women, contribut-
ing to a decrease of 4% in DPPs in men and 2% in women 
(Table 2). Adverse trends were observed in diabetes mellitus 
and BMI, with the prevalence of diabetes mellitus increasing 
from 5.3% to 10.2% in men and 6.2% to 6.3% in women and 
mean BMI increasing from 26.2 to 27.8 kg/m2 in men and 26.6 
to 28.2 kg/m2 in women between 1995 and 2008. These 2 risk 
factors together generated a 25% increase in DPPs in men and 
7% in women. In men, the prevalence of smoking decreased, 
contributing to a 11% decrease in DPPs, whereas it increased 
in women, resulting in 2% extra deaths.
Sensitivity Analyses
The proportional contributions of specific treatments and risk 
factor changes to the overall decrease in CHD mortality in 
Portugal between 1995 and 2008 remained relatively consis-
tent in the sensitivity analysis (Figure 2).
Discussion
We quantified the contribution of risk factors and treatments to 
the decline in CHD mortality in Portugal, a country in South-
ern Europe where the CHD mortality rates are much lower 
than in Northern Europe or the United States.1,10 CHD mortal-
ity rates in Portugal fell by >25% between 1995 and 2008. The 
reductions attributable to evidence-based therapies accounted 
for approximately half of the DPPs. Approximately 42% of 
the fall was because of the trends in major risk factors, mainly 
SBP, although the rise in the prevalence of diabetes melli-
tus and mean BMI in both sexes and in smoking prevalence 
among women generated additional deaths.
The observed decrease in the mortality in the period con-
sidered was noteworthy,1 despite the lower rates in the base-
line year, even when compared with other Southern European 
countries with low baseline CHD mortality rates where this 
model was applied, namely, Spain (1988–2005)15 and Italy 
(1980–2000).14 The proportional contribution of treatments 
and risk factors for CHD mortality trends in Portugal is to 
some extent different from the aforementioned countries 
mainly because of a higher contribution of treatments. Most 
of the previous studies have consistently shown either a simi-
lar or slightly higher contribution of reduction in population 
risk factor levels compared with treatments,10,14,15 but in the 
Icelandic population, the proportional contribution of risk fac-
tors was much higher than in Portugal.30 However, compari-
sons with previous models must be interpreted with caution 
because of different time periods being assessed and the pace 
of evolution in treatments in the past 15 years.31
Advances in CHD diagnosis and treatment allowed the 
earlier identification of cases, the diagnoses of milder cases 
of disease, and consequently the decrease in the proportion 
of fatal acute events. The increasing number of centers with 
catheterization laboratory and the implementation of the coro-
nary fast track system in the early 2000s in Portugal allowed 
for a more effective use of percutaneous coronary intervention 
and other invasive treatments.9 Also, the period of analysis 
covers a time of steep changes in the availability and uptake 
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of drugs for the initial treatments after an acute coronary 
syndrome and for secondary prevention after an AMI. The 
prescription of double antiplatelet therapy during hospi-
talization increased significantly over time, from 33% in 
2002 to 95% in 2008. The same trend was observed in the 
prescription of β-blockers, angiotensin-converting enzyme 
inhibitors, and statins.9 Also, recommended combined 
therapy for secondary prevention of events at hospital dis-
charge (including the combination of double antiplatelets, 
angiotensin-converting enzyme inhibitors, β-blockers, 
and statins) increased from 14% in 2002 to 63% in 2008.9 
These important recent changes may explain the larger 
contribution of treatments, compared with risk factors, in 
our population.
Portugal has been described as one of the countries with 
the highest median blood pressure levels,32,33 and in 2003, 
3 million adults (42%) had hypertension.34 However, from 
1975 to 2005, mean SBP decreased remarkably in men after 
middle age and in women at all ages, adding up to a cumula-
tive decrease of 22 and 32 mm Hg in SBP at an average age 
of 70 years, in men and women, respectively.6 The propor-
tion of hypertensives treated in Portugal increased in the past 
few decades, and in the beginning of the 2000s, almost half 
of hypertensives were treated.19,34 The high prevalence of 
hypertension results in a large impact of any improvement in 
treatment rates because of the high number of people expe-
riencing such benefit. Although the European guidelines in 
1995 already recommended the prescription of pharmacologi-
cal treatment aiming the target used today (SBP <140 mm Hg 
and diastolic <90 mm Hg),35 pharmacological treatment for 
primary prevention in daily practice focused on high-risk indi-
viduals, and consequently only a relatively small proportion 
of the population was treated.
Total cholesterol has decreased slightly during the past 
years in Portugal,20,22 as in most other European countries.36 
The overall decline in cholesterol level does not yet reflect 
the recent trends in the food intake in Portugal, where the 
consumption of fish and soup is decreasing and the consump-
tion of fat-containing foods, such as meat and snacks, is 
increasing steeply.37 However, other developed countries have 
shown even higher decreases in cholesterol levels despite the 
adverse trends in food intake.14,15 When compared with other 
Mediterranean countries, we report a lower contribution of 
changes in the cholesterol after excluding the effect of phar-
macological treatment (10% in Portugal versus 31% in Spain 
and 23% in Italy). The higher contribution of statins (6% in 
Portugal versus 1% in Spain and 3% in Italy) and the relatively 
faster trends in the diet transition toward a more unhealthy 
diet38 suggest that in Portugal the reduction in total choles-
terol was achieved mainly through the use of pharmacological 
treatment. In 1995, the use of statins was residual in Portugal 
(4.43 defined daily doses per 1000 inhabitants per day), but 
because of an average annual growth of 35%, in 2004, the 
number increased significantly (60.73 defined daily doses per 
1000 inhabitants per day).39
The results of this study reflect the recent trends in smoking 
prevalence, which place Portuguese women in stage II of the 
smoking epidemic (characterized by a rapid increase of the 
prevalence of smoking along with few deaths attributable to 
smoking), whereas men are at a later stage, between stages 
III and IV (characterized by a decrease in the prevalence of 
smoking and a peak in smoking-attributable mortality).7 As 
expected, we found differences in the trends in smoking prev-
alence trends according to sex. Although smoking prevalence 
in men decreased, it increased among women, resulting in 35 
additional coronary deaths.
Figure 2. Proportion of all coronary heart disease deaths prevented or postponed explained by the model, which were attributed to the 
contribution of treatments and risk factors in Portugal, 1995 to 2008. The diamonds are the best model estimate and the vertical lines the 
extreme minimum and maximum estimates in sensitivity analysis. CABG indicates coronary artery bypass graft; DPPs, deaths prevented 
or postponed; HT, hypertension; and PCI, percutaneous coronary intervention.
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Apart from smoking among women, 2 other major risk fac-
tors led to increases in CHD deaths. The contribution of BMI 
to the increase in the total number of CHD deaths was impor-
tant, as well as the dramatic increase in diabetes mellitus prev-
alence. These trends are consistent with recent studies in other 
industrialized countries.14,15 Efforts to address obesity and 
diabetes mellitus should therefore receive particular attention 
in future policies to improve the public’s health, especially 
because the prevalence of overweight/obesity in younger age 
groups of the Portuguese population is increasing.8,21
Modeling studies have several potential strengths, includ-
ing the ability to transparently integrate and simultaneously 
consider huge amounts of data from many sources and test-
ing the uncertainty inherent to such complexity by sensitivity 
analyses. However, models are highly dependent on the qual-
ity of data available. We made all the efforts to include in this 
model the most representative and unbiased data available in 
Portugal. We performed a systematic review that aimed to crit-
ically summarize the evidence from studies that quantified the 
distribution and frequency of all risk factors included in this 
model.6,7,21,22 It was not possible to obtain representative data 
of treatment uptake in Portugal in 1995 because most of the 
existing studies reflected the usual care in higher quality spe-
cialized centers, which limits their generalizability. Therefore, 
we included estimates that represented a general consensus of 
a group of experts who critically evaluated the evidence avail-
able. The majority of the treatment data for 2008 were from 
EURHOBOP, a study that reported data from 3009 patients 
with acute coronary syndrome consecutively recruited in 10 
Portuguese hospitals.17 Even so, in some cases, the data used 
were obtained from studies possibly constrained by geographic 
or selection bias. In addition, because we used data from dif-
ferent studies for the first and last years, the variations in the 
study designs and study populations can potentially influence 
the results of the model. The majority of treatment uptake 
and case-fatality rates were based on data from the United 
Kingdom and the United States because little or no specific 
Portuguese data were available. Although major efforts were 
made to address overlaps, residual double counting of some 
individual patients remains possible. We also assumed that, 
after adjustments for imperfect compliance,25 the efficacy of 
treatments in randomized controlled trials could be general-
ized to population effectiveness in usual clinical practice. All 
the assumptions that we made are presented in the Appendix 
in the online-only Data Supplement (Tables 1 and 2). Finally, 
we did not consider the direct effect of trends in socioeco-
nomic status, compliance, or access to care. Although the 
trends in socioeconomic status and access to care are some-
how indirectly measured because of their effect on the varia-
tion of risk factors and treatments, the variation in compliance 
was not assessed, and we do not have data in the Portuguese 
population to be able to estimate in which direction and to 
which extent this may have affected the results.
In conclusion, CHD mortality in Portugal decreased 25% 
between 1995 and 2008. Overall, treatments explained half 
of the overall decline in CHD deaths, and risk factor changes 
were more important among women than men. The decrease in 
mean SBP and increase in hypertension treatment contributed 
most to the CHD mortality decline. These results encourage 
the use of comprehensive efforts to actively promote primary 
prevention, particularly a healthy diet and tobacco control, 
as well as maximizing the population coverage of effective 
treatments.
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